Informe completo: Stereotactic ablative radiotherapy to treat people with primary kidney cancer
Resumen: Stereotactic ablative radiotherapy (SABR) for renal cell carcinoma (RCC)
Objetivo: Identify and summarize evidence addressing the following review question: what is the clinical and cost effectiveness of stereotactic ablative radiotherapy (SABR) for primary kidney cancer compared to standard care?
Autoría: Health Technology Wales (HTW)
Idioma: inglés
Fuente: INAHTA
Año de publicación: 2022